表紙
市場調査レポート

高グレード神経膠腫:パイプライン製品の分析

High-Grade Glioma - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 271830
出版日 ページ情報 英文 159 Pages
即納可能
価格
本日の銀行送金レート: 1USD=104.18円で換算しております。
Back to Top
高グレード神経膠腫:パイプライン製品の分析 High-Grade Glioma - Pipeline Review, H2 2015
出版日: 2015年12月16日 ページ情報: 英文 159 Pages
概要

高グレード神経膠腫(HGG)は中枢神経系(CNS)の腫瘍で、脳・脊椎の悪性変換細胞より発症します。主な症状として、発達遅滞や頭痛・背痛、吐き気・嘔吐、めまい、歩行障害、視力低下、集中力低下、眠気、睡眠障害、不規則な食欲、麻痺・てんかんなどが挙げられます。主な治療法には、化学療法や放射線治療などがあります。

当レポートでは、世界各国での高グレード神経膠腫(グリオーマ)治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

高グレード神経膠腫(グリオーマ)の概要

治療薬の開発

  • 高グレード神経膠腫向けパイプライン製品:概要
  • 高グレード神経膠腫向けパイプライン製品:比較分析

各企業で開発中の高グレード神経膠腫治療薬

大学/研究機関で研究中の高グレード神経膠腫治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階の製品

高グレード神経膠腫治療薬:開発中の製品の一覧(企業別)

高グレード神経膠腫治療薬:研究中の製品の一覧(大学/研究機関別)

高グレード神経膠腫治療薬の開発に従事している企業

  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc
  • Genentech, Inc.
  • Bayer AG
  • Virttu Biologics Limited
  • AngioChem Inc.
  • Stemline Therapeutics, Inc.
  • TAU Therapeutics, LLC
  • Tocagen Inc.
  • AROG Pharmaceuticals LLC

高グレード神経膠腫:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • ニンテダニブ
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • ANG-1005
  • ダブラフェニブ+トラメチニブ
  • 高グレード神経膠腫・肝臓移植向け遺伝子治療
  • 樹状細胞ワクチン
  • トシル酸ソラフェニブ
  • vocimagene amiretrorepvec + フルシトシンER(延長放出)
  • SL-701
  • ベシル酸クレノラニブ
  • ミベフラジル二塩酸塩
  • GDC-0084
  • HSV-1716
  • TBX-01
  • Toca

高グレード神経膠腫治療薬:パイプライン製品の最新動向

高グレード神経膠腫治療薬:開発が休止状態の製品

高グレード神経膠腫関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース(全2件)

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7463IDB

Summary

Global Markets Direct's, 'High-Grade Glioma - Pipeline Review, H2 2015', provides an overview of the High-Grade Glioma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for High-Grade Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High-Grade Glioma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of High-Grade Glioma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for High-Grade Glioma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the High-Grade Glioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the High-Grade Glioma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for High-Grade Glioma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding High-Grade Glioma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • High-Grade Glioma Overview
  • Therapeutics Development
    • Pipeline Products for High-Grade Glioma - Overview
    • Pipeline Products for High-Grade Glioma - Comparative Analysis
  • High-Grade Glioma - Therapeutics under Development by Companies
  • High-Grade Glioma - Therapeutics under Investigation by Universities/Institutes
  • High-Grade Glioma - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • High-Grade Glioma - Products under Development by Companies
  • High-Grade Glioma - Products under Investigation by Universities/Institutes
  • High-Grade Glioma - Companies Involved in Therapeutics Development
    • AngioChem Inc.
    • Arog Pharmaceuticals, Inc.
    • Bayer AG
    • Boehringer Ingelheim GmbH
    • Cavion LLC
    • Kinex Pharmaceuticals, LLC
    • Merrimack Pharmaceuticals, Inc.
    • Millennium Pharmaceuticals, Inc.
    • Nektar Therapeutics
    • Novartis AG
    • Oncolytics Biotech Inc.
    • Sanofi
    • Stemline Therapeutics, Inc.
    • Targepeutics, Inc.
    • Tocagen Inc.
    • Virttu Biologics Limited
  • High-Grade Glioma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • alisertib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • crenolanib besylate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Dendritic Cell Therapy for Gliomas - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Dendritic Cell Therapy for Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dianhydrogalactitol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • etirinotecan pegol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • flucytosine + TBio-01 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GB-13 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for High-Grade Glioma and Liver Transplantation - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HSV-1716 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • irinotecan hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • irinotecan hydrochloride + TBio-02 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KX-02 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mibefradil dihydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nintedanib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • paclitaxel trevatide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pelareorep - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • plerixafor - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SL-701 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sorafenib tosylate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Toca-Gamma - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Toca-RNAi - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vocimagene amiretrorepvec + flucytosine ER - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • High-Grade Glioma - Recent Pipeline Updates
  • High-Grade Glioma - Dormant Projects
  • High-Grade Glioma - Discontinued Products
  • High-Grade Glioma - Product Development Milestones
    • Featured News & Press Releases
      • Jun 01, 2015: Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma
      • May 28, 2015: Cavion to Present Clinical Trial Data at ASCO
      • May 31, 2014: Positive Data from Phase 2 Trial of NKTR-102 in Patients with Avastin -Refractory High-Grade Glioma Presented at 50th ASCO Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for High-Grade Glioma, H2 2015
  • Number of Products under Development for High-Grade Glioma - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • High-Grade Glioma - Pipeline by AngioChem Inc., H2 2015
  • High-Grade Glioma - Pipeline by Arog Pharmaceuticals, Inc., H2 2015
  • High-Grade Glioma - Pipeline by Bayer AG, H2 2015
  • High-Grade Glioma - Pipeline by Boehringer Ingelheim GmbH, H2 2015
  • High-Grade Glioma - Pipeline by Cavion LLC, H2 2015
  • High-Grade Glioma - Pipeline by Kinex Pharmaceuticals, LLC, H2 2015
  • High-Grade Glioma - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2015
  • High-Grade Glioma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
  • High-Grade Glioma - Pipeline by Nektar Therapeutics, H2 2015
  • High-Grade Glioma - Pipeline by Novartis AG, H2 2015
  • High-Grade Glioma - Pipeline by Oncolytics Biotech Inc., H2 2015
  • High-Grade Glioma - Pipeline by Sanofi, H2 2015
  • High-Grade Glioma - Pipeline by Stemline Therapeutics, Inc., H2 2015
  • High-Grade Glioma - Pipeline by Targepeutics, Inc., H2 2015
  • High-Grade Glioma - Pipeline by Tocagen Inc., H2 2015
  • High-Grade Glioma - Pipeline by Virttu Biologics Limited, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • High-Grade Glioma Therapeutics - Recent Pipeline Updates, H2 2015
  • High-Grade Glioma - Dormant Projects, H2 2015
  • High-Grade Glioma - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for High-Grade Glioma, H2 2015
  • Number of Products under Development for High-Grade Glioma - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Molecule Types, H2 2015
  • Number of Products by Stage and Molecule Types, H2 2015
Back to Top